Clinical Trial

Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense

Study acronym: TibuSHIELD
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The study is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of tibulizumab over 16 weeks (Period 1) in adults with hidradenitis suppurativa, followed by a 16-week open-label extension period in which all participants will receive tibulizumab (Period 2)
Protocol Amendment History 2 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-07-01
notable Trial sites expanded: 56 -> 61 locations 2026-07-01
Trial Details
NCT Number NCT06993610
Lead Sponsor Zura Bio Inc
Conditions Hidradenitis Suppurativa (HS)
Enrollment 225 participants
Start Date 2025-05-16
Primary Completion 2026-11 (estimated)
Study Completion 2027-04 (estimated)
Updated on ClinicalTrials.gov 2026-06-30